

CONSORT Statement 2006 - Checklist for Non-inferiority and Equivalence Trials



Items to include when reporting a non-inferiority or equivalence randomized trial

Please note: This is an open-label phase 2/3 study that evaluates safety and non-inferiority of study vaccination in 2 cohorts of participants. The checklist has been correspondingly completed to indicate compliance with guidelines where applicable. NA=not applicable.

PAPER SECTION And topic	Item	Descriptor	Reported on Page #
TITLE & ABSTRACT	1	<u>How participants were allocated to interventions</u> (e.g., "random allocation", "randomized", or "randomly assigned"), specifying that the trial is a non-inferiority or equivalence trial.	NA: not a randomized trial; participants were allocated to study vaccine as described (pg. 5, & Fig. 1, pg.19)
INTRODUCTION Background	2	<u>Scientific background and explanation of rationale</u> , including the rationale for using a non-inferiority or equivalence design.	4; Supplement pg.4-6
METHODS Participants	3	<u>Eligibility criteria for participants</u> (detailing whether participants in the non-inferiority or equivalence trial are similar to those in any trial(s) that established efficacy of the reference treatment) and the <u>settings and locations where the data were collected</u> .	5; Supplement, pg. 4-6
Interventions	4	<u>Precise details of the interventions intended for each group</u> detailing whether the reference treatment in the non-inferiority or equivalence trial is identical (or very similar) to that in any trial(s) that established efficacy, <u>and how and when they were actually administered</u> .	5; Supplement pg. 4
Objectives	5	<u>Specific objectives and hypotheses</u> , including the hypothesis concerning non-inferiority or equivalence.	7-9; Supplement, pg. 6-9 and 16-17
Outcomes	6	<u>Clearly defined primary and secondary outcome measures</u> detailing whether the outcomes in the non-inferiority or equivalence trial are identical (or very similar) to those in any trial(s) that established efficacy of the reference treatment and, when applicable, any <u>methods used to enhance the quality of measurements</u> (e.g., multiple observations, training of assessors).	7-9; Supplement, pg. 6-9
Sample size	7	<u>How sample size was determined</u> detailing whether it was calculated using a non-inferiority or equivalence criterion and specifying the margin of equivalence with the rationale for its choice. When applicable, <u>explanation of any interim analyses and stopping rules</u> (and whether related to a non-inferiority or equivalence hypothesis).	Supplement, pg. 7
Randomization -- Sequence generation	8	<u>Method used to generate the random allocation sequence</u> , including details of any restrictions (e.g., blocking, stratification)	NA: not randomized
Randomization -- Allocation concealment	9	<u>Method used to implement the random allocation sequence</u> (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned.	NA: not randomized
Randomization -- Implementation	10	<u>Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups</u> .	NA: not randomized
Blinding (masking)	11	<u>Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment</u> . If done, <u>how the success of blinding was evaluated</u> .	NA: open-label trial
Statistical methods	12	<u>Statistical methods used to compare groups for primary outcome(s)</u> , specifying whether a one or two-sided confidence interval approach was used. <u>Methods for additional analyses</u> , such as subgroup analyses and adjusted analyses.	7-9; Supplement, pg. 6-8

RESULTS Participant flow	13	<u>Flow of participants through each stage</u> (a diagram is strongly recommended). Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. <u>Describe protocol deviations from study as planned, together with reasons.</u>	16; Figure 1
Recruitment	14	<u>Dates defining the periods of recruitment and follow-up.</u>	9-10
Baseline data	15	<u>Baseline demographic and clinical characteristics of each group.</u>	9 and Table 1, pg. 20
Numbers analyzed	16	<u>Number of participants (denominator) in each group included in each analysis and whether the analysis was “intention-to-treat” and/or alternative analyses were conducted.</u> State the results in absolute numbers when feasible (e.g., 10/20, not 50%).	Table 2 pg. 21; Supplement, pg. 12-15 and 22-28
Outcomes and estimation	17	<u>For each primary and secondary outcome, a summary of results for each group, and the estimated effect size and its precision</u> (e.g., 95% confidence interval). <i>For the outcome(s) for which non-inferiority or equivalence is hypothesized, a figure showing confidence intervals and margins of equivalence may be useful.</i>	11-12, Table 2; 21; Supplement, p. 12-15 and 19-28
Ancillary analyses	18	<u>Address multiplicity by reporting any other analyses performed</u> , including subgroup analyses and adjusted analyses, indicating those pre-specified and those exploratory.	7-9; Supplement, pg. 6-8
Adverse events	19	<u>All important adverse events or side effects in each intervention group.</u>	10 and Figure 2 pg.17
DISCUSSION Interpretation	20	<u>Interpretation of the results</u> , taking into account the <i>non-inferiority or equivalence hypothesis and any other study hypotheses</i> , sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes.	9-12
Generalizability	21	<u>Generalizability (external validity) of the trial findings.</u>	14-15
Overall evidence	22	<u>General interpretation of the results in the context of current evidence.</u>	13-14

www.consort-statement.org